Bruce D. Cheson

13.4k total citations · 4 hit papers
130 papers, 9.6k citations indexed

About

Bruce D. Cheson is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Bruce D. Cheson has authored 130 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pathology and Forensic Medicine, 58 papers in Genetics and 36 papers in Oncology. Recurrent topics in Bruce D. Cheson's work include Lymphoma Diagnosis and Treatment (66 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Multiple Myeloma Research and Treatments (11 papers). Bruce D. Cheson is often cited by papers focused on Lymphoma Diagnosis and Treatment (66 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Multiple Myeloma Research and Treatments (11 papers). Bruce D. Cheson collaborates with scholars based in United States, Italy and Germany. Bruce D. Cheson's co-authors include Nancy L. Harris, Julie M. Vose, George P. Canellos, Fernando Cabanillas, Richard I. Fisher, Jamés O. Armitage, Wolfgang Hiddemann, William Carter, Sandra J. Horning and Margaret A. Shipp and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Bruce D. Cheson

122 papers receiving 9.4k citations

Hit Papers

Report of an Internationa... 1990 2026 2002 2014 1999 2007 2000 1990 500 1000 1.5k 2.0k 2.5k

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Bruce D. Cheson 5.3k 3.7k 3.0k 2.9k 1.9k 130 9.6k
Morton Coleman 4.8k 0.9× 3.0k 0.8× 3.3k 1.1× 2.1k 0.7× 1.6k 0.9× 306 8.2k
Myron S. Czuczman 6.5k 1.2× 4.6k 1.2× 3.5k 1.2× 1.3k 0.5× 2.0k 1.1× 241 10.4k
Luca Baldini 3.7k 0.7× 2.5k 0.7× 2.8k 0.9× 1.9k 0.7× 2.3k 1.2× 261 7.8k
Michael Crump 5.6k 1.0× 5.3k 1.4× 2.4k 0.8× 1.0k 0.4× 1.6k 0.9× 310 9.8k
Brad S. Kahl 7.8k 1.5× 5.6k 1.5× 5.1k 1.7× 1.5k 0.5× 2.4k 1.3× 385 11.3k
Jorge Romaguera 7.1k 1.3× 5.4k 1.4× 3.3k 1.1× 950 0.3× 1.6k 0.8× 281 9.8k
Eric L. Sievers 3.3k 0.6× 5.1k 1.4× 1.3k 0.4× 2.6k 0.9× 2.9k 1.5× 101 10.3k
Steven Le Gouill 3.7k 0.7× 3.3k 0.9× 1.7k 0.6× 1.7k 0.6× 2.1k 1.1× 312 7.2k
Francesc Bosch 5.6k 1.0× 3.4k 0.9× 4.3k 1.4× 1.2k 0.4× 2.0k 1.0× 243 8.7k
Fredrick B. Hagemeister 6.1k 1.2× 4.3k 1.2× 2.7k 0.9× 925 0.3× 791 0.4× 257 8.5k

Countries citing papers authored by Bruce D. Cheson

Since Specialization
Citations

This map shows the geographic impact of Bruce D. Cheson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce D. Cheson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce D. Cheson more than expected).

Fields of papers citing papers by Bruce D. Cheson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce D. Cheson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce D. Cheson. The network helps show where Bruce D. Cheson may publish in the future.

Co-authorship network of co-authors of Bruce D. Cheson

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce D. Cheson. A scholar is included among the top collaborators of Bruce D. Cheson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce D. Cheson. Bruce D. Cheson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheson, Bruce D., et al.. (2021). Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic. Cancer Management and Research. Volume 13. 677–692. 15 indexed citations
2.
Liu, T. Y. Alvin, et al.. (2020). Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature. Leukemia Research Reports. 14. 100200–100200.
3.
Press, Oliver W., Joseph M. Unger, Lisa M. Rimsza, et al.. (2013). A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab. Clinical Cancer Research. 19(23). 6624–6632. 32 indexed citations
4.
Liu, Hui, Jeffrey L. Johnson, Gregory Malnassy, et al.. (2011). Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 97(4). 579–585. 59 indexed citations
5.
Goswami, Trishna, et al.. (2010). The Sarcoid-Lymphoma Syndrome. Clinical Lymphoma Myeloma & Leukemia. 10(4). 241–247. 24 indexed citations
6.
Juweid, Malik E., Sigrid Stroobants, Otto S. Hoekstra, et al.. (2007). Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology. 25(5). 571–578. 967 indexed citations breakdown →
7.
Cheson, Bruce D.. (2006). Radioimmunotherapy of Non-Hodgkins Lymphomas. Current Drug Targets. 7(10). 1293–1300. 12 indexed citations
8.
Gertz, Morie A., Martha Q. Lacy, Angela Dispenzieri, et al.. (2002). A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid. 9(1). 24–30. 41 indexed citations
9.
Cheson, Bruce D., et al.. (2000). Management of Chronic Lymphocytic Leukaemia. Drugs & Aging. 16(1). 9–27. 32 indexed citations
10.
Cheson, Bruce D.. (1998). Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leukemia Research. 22. S17–S21. 24 indexed citations
11.
Wilson, Wyndham H., Bruce A. Chabner, G Bryant, et al.. (1995). Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.. Journal of Clinical Oncology. 13(2). 381–386. 46 indexed citations
12.
Cheson, Bruce D.. (1993). Purine Analogs in Lymphoproliferative Disorders. Leukemia & lymphoma. 11(sup2). 153–159. 6 indexed citations
13.
Cheson, Bruce D.. (1991). Chronic lymphocytic leukemia and hairy-cell leukemia. Current Opinion in Oncology. 3(1). 54–62. 4 indexed citations
14.
Cheson, Bruce D.. (1991). New modalities of therapy in chronic lymphocytic leukemia. Critical Reviews in Oncology/Hematology. 11(3). 167–177. 4 indexed citations
15.
Cheson, Bruce D., et al.. (1991). Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia. Leukemia & lymphoma. 5(sup1). 119–122. 9 indexed citations
16.
Cheson, Bruce D.. (1990). The Myelodysplastic Syndromes: Current Approaches to Therapy. Annals of Internal Medicine. 112(12). 932–941. 85 indexed citations
17.
Simon, Richard, Sylvain Durrleman, Richard T. Hoppe, et al.. (1990). Prognostic factors for patients with diffuse large cell or immunoblastic non‐Hodgkin's lymphomas: Experience of the non‐Hodgkin's lymphoma pathologic classification project. Medical and Pediatric Oncology. 18(2). 89–96. 11 indexed citations
18.
Cheson, Bruce D.. (1989). Current approaches to the chemotherapy of B‐cell chronic lymphocytic leukemia: A review. American Journal of Hematology. 32(1). 72–77. 11 indexed citations
19.
Grem, Jean L., Bruce D. Cheson, Susan A. King, Brian Leyland‐Jones, & M Suffness. (1988). Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure?. JNCI Journal of the National Cancer Institute. 80(14). 1095–1103. 28 indexed citations
20.
Cheson, Bruce D., et al.. (1977). The oxidative killing mechanisms of the neutrophil.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 3. 1–65. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026